BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rosati M, Terpos E, Ntanasis-Stathopoulos I, Agarwal M, Bear J, Burns R, Hu X, Korompoki E, Donohue D, Venzon DJ, Dimopoulos MA, Pavlakis GN, Felber BK. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. Front Immunol 2021;12:793953. [PMID: 34899762 DOI: 10.3389/fimmu.2021.793953] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang M, Zhou B, Fan Q, Zhou X, Liao X, Lin J, Ma Z, Dong J, Wang H, Ge X, Ju B, Zhang Z. Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination. Emerg Microbes Infect 2023;12:2151381. [PMID: 36444724 DOI: 10.1080/22221751.2022.2151381] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
2 Cinicola BL, Piano Mortari E, Zicari AM, Agrati C, Bordoni V, Albano C, Fedele G, Schiavoni I, Leone P, Fiore S, Capponi M, Conti MG, Petrarca L, Stefanelli P, Spalice A, Midulla F, Palamara AT, Quinti I, Locatelli F, Carsetti R. The BNT162b2 vaccine induces humoral and cellular immune memory to SARS-CoV-2 Wuhan strain and the Omicron variant in children 5 to 11 years of age. Front Immunol 2022;13:1094727. [PMID: 36591287 DOI: 10.3389/fimmu.2022.1094727] [Reference Citation Analysis]
3 Kongkamol C, Ingviya T, Chusri S, Surasombatpattana S, Kwanyuang A, Chaichulee S, Sophark I, Seesong C, Sorntavorn T, Detpreechakul T, Phaiboonpornpong P, Krainara K, Sathirapanya P, Sathirapanya C. Integrative Effects between a Bubble and Seal Program and Workers' Compliance to Health Advice on Successful COVID-19 Transmission Control in a Factory in Southern Thailand. Int J Environ Res Public Health 2022;19. [PMID: 36554271 DOI: 10.3390/ijerph192416391] [Reference Citation Analysis]
4 Liu WD, Wang JT, Chao TL, Ieong SM, Tsai YM, Kuo PH, Tsai MJ, Chen YJ, Li GC, Ho SY, Chen HH, Huang YS, Hung CC, Chen YC, Chang SY, Chang SC. Evolution of neutralizing antibodies and cross-activity against different variants of SARS-CoV-2 in patients recovering from COVID-19. J Formos Med Assoc 2022:S0929-6646(22)00436-3. [PMID: 36496300 DOI: 10.1016/j.jfma.2022.11.015] [Reference Citation Analysis]
5 Jacobsen EM, Fabricius D, Class M, Topfstedt F, Lorenzetti R, Janowska I, Schmidt F, Staniek J, Zernickel M, Stamminger T, Dietz AN, Zellmer A, Hecht M, Rauch P, Blum C, Ludwig C, Jahrsdörfer B, Schrezenmeier H, Heeg M, Mayer B, Seidel A, Groß R, Münch J, Kirchhoff F, Bode SFN, Strauss G, Renk H, Elling R, Stich M, Voll RE, Tönshof B, Franz AR, Henneke P, Debatin KM, Rizzi M, Janda A. High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection. Nat Commun 2022;13:7315. [PMID: 36437276 DOI: 10.1038/s41467-022-35055-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Rosati M, Terpos E, Bear J, Burns R, Devasundaram S, Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Dimopoulos MA, Pavlakis GN, Felber BK. Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom's Macroglobulinemia after BNT162b2 Booster Vaccination. Cancers (Basel) 2022;14. [PMID: 36497296 DOI: 10.3390/cancers14235816] [Reference Citation Analysis]
7 Yildiz Y, Ozger HS, Senol E, Karakus R, Buyukkoruk M, Altin FB, Ozcan FZ, Yaman M, Oruklu N, Yucel AA, Bagriacik EU. Evaluation of long-term antibody kinetics in healthcare workers vaccinated with inactivated COVID-19 Vero cell vaccine (CoronaVac), a propensity score-matched observational study. Int J Infect Dis 2022;122:99-106. [PMID: 35568368 DOI: 10.1016/j.ijid.2022.05.007] [Reference Citation Analysis]
8 Di Chiara C, Cantarutti A, Costenaro P, Donà D, Bonfante F, Cosma C, Ferrarese M, Cozzani S, Petrara MR, Carmona F, Liberati C, Palma P, Di Salvo G, De Rossi A, Plebani M, Padoan A, Giaquinto C. Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection. JAMA Netw Open 2022;5:e2221616. [PMID: 35816313 DOI: 10.1001/jamanetworkopen.2022.21616] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Prasithsirikul W, Nopsopon T, Phutrakool P, Suwanwattana P, Kantagowit P, Pongpirul W, Jongkaewwattana A, Pongpirul K. ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis. Vaccines (Basel) 2022;10:959. [PMID: 35746567 DOI: 10.3390/vaccines10060959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Bergamaschi C, Pagoni M, Rosati M, Angel M, Tzannou I, Vlachou M, Darmani I, Ullah A, Bear J, Devasundaram S, Burns R, Baltadakis I, Gigantes S, Dimopoulos MA, Pavlakis GN, Terpos E, Felber BK. Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies. Front Immunol 2022;13:899972. [PMID: 35693807 DOI: 10.3389/fimmu.2022.899972] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Pilz S, Theiler-Schwetz V, Trummer C, Krause R, Ioannidis JPA. SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. Environ Res 2022;209:112911. [PMID: 35149106 DOI: 10.1016/j.envres.2022.112911] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 73.0] [Reference Citation Analysis]
12 Smirnov VS, Lyalina LV, Milichkina AM, Khamitova IV, Zueva EV, Ivanov VA, Zaguzov VS, Totolian AA. Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population. Viruses 2022;14:913. [DOI: 10.3390/v14050913] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Labropoulou S, Vassilaki N, Milona RS, Terpos E, Politou M, Pappa V, Pagoni M, Grouzi E, Dimopoulos MA, Mentis A, Emmanouil M, Angelakis E. Characterizing Kinetics and Avidity of SARS-CoV-2 Antibody Responses in COVID-19 Greek Patients. Viruses 2022;14:758. [DOI: 10.3390/v14040758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Lin H, Zhang J, Dong S, Liu Y, Liu P, Gao GF, Liu WJ, Wu G. An adjusted ELISpot-based immunoassay for evaluation of SARS-CoV-2-specific T-cell responses. Biosafety and Health 2022. [DOI: 10.1016/j.bsheal.2022.04.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Fung K, Lai S, Lin T, Tseng T. Antigen–Antibody Complex-Guided Exploration of the Hotspots Conferring the Immune-Escaping Ability of the SARS-CoV-2 RBD. Front Mol Biosci 2022;9:797132. [DOI: 10.3389/fmolb.2022.797132] [Reference Citation Analysis]
16 Flores-Vega VR, Monroy-Molina JV, Jiménez-Hernández LE, Torres AG, Santos-Preciado JI, Rosales-Reyes R. SARS-CoV-2: Evolution and Emergence of New Viral Variants. Viruses 2022;14:653. [PMID: 35458383 DOI: 10.3390/v14040653] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
17 Van Elslande J, Oyaert M, Lorent N, Weygaerde YV, Van Pottelbergh G, Godderis L, Van Ranst M, André E, Padalko E, Lagrou K, Vandendriessche S, Vermeersch P. Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. Diagnostic Microbiology and Infectious Disease 2022. [DOI: 10.1016/j.diagmicrobio.2022.115659] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]